Guardant Health Current Ratio 2017-2021 | GH

Current and historical current ratio for Guardant Health (GH) from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Guardant Health current ratio for the three months ending June 30, 2021 was 19.57.
Guardant Health Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $1.89B $0.10B 19.57
2021-03-31 $2.03B $0.10B 21.29
2020-12-31 $1.89B $0.07B 28.27
2020-09-30 $1.09B $0.07B 15.11
2020-06-30 $1.01B $0.07B 14.42
2020-03-31 $0.61B $0.08B 7.38
2019-12-31 $0.60B $0.07B 8.21
2019-09-30 $0.58B $0.07B 8.60
2019-06-30 $0.60B $0.06B 10.59
2019-03-31 $0.51B $0.05B 10.63
2018-12-31 $0.47B $0.05B 9.99
2018-09-30 $0.30B $0.03B 9.27
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
2016-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.077B $0.287B
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76